Drug Profile
Research programme: autologous cultured blood vessel cells - inRegen
Alternative Names: Neo-vessel ReplacementLatest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Tengion
- Developer inRegen
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Vascular-disorders in USA
- 10 Jul 2013 Research programme: autologous cultured blood vessel cells - Tengion is available for licensing as of 10 Jul 2013. http://www.tengion.com
- 01 Jul 2013 Early research in Vascular disorders in USA (unspecified route)